Supernus Posts Record Third-Quarter Revenue of $226.8 Million, Up 18%, as Indivior Merger Nears November 2 Close
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a Rockville, Maryland-based biopharmaceutical company focused on central nervous system diseases, on October 29 announced financial results for the third quarter of 2026. Total revenues reached a record $226.8 million, an 18 percent increase over the same period last year. Net earnings were $20.9 million, or $0.35 per diluted share, compared with a net loss of $45.1 million, or $0.80 per share, in the third quarter of 2025.
Combined revenues of the company's four growth products rose to $192.2 million in the quarter, up 29 percent. Net sales of the ADHD treatment Qelbree increased 12 percent to $90.8 million, with prescriptions up 18 percent. GOCOVRI net sales reached an all-time high of $42.6 million. ONAPGO net sales were $17.1 million, up 151 percent; the U.S. Food and Drug Administration (FDA) has recognized seven years of orphan-drug exclusivity for ONAPGO, and the company has submitted a supplemental New Drug Application for a second supplier. Collaboration revenue from ZURZUVAE was $41.7 million.
Cash, cash equivalents and current marketable securities were approximately $359.5 million as of September 30, 2026. The company raised its stand-alone full-year 2026 guidance, putting total revenues at $875 million to $900 million, up from $860 million to $890 million.
Supernus's all-stock merger with Indivior Pharmaceuticals, Inc. was approved by the shareholders of both companies on October 15, 2026, and is expected to close on November 2, 2026. The combined company, to be named Supernus, Inc., is expected to realize $125 million in annual cost synergies and will begin trading on Nasdaq under the ticker SUPN on November 3. The company noted that if the merger closes as expected, the stand-alone guidance will no longer apply.
"Our strong operating execution year-to-date delivered total revenue growth of 29%, which shows the continued momentum across our commercial portfolio, specifically our growth products," said Jack Khattar, President and Chief Executive Officer of Supernus. "We look forward to closing the merger with Indivior next week, which will create a diverse CNS biopharmaceutical leader."
Source: GSM · USA (original Chinese edition)
Photo: 图：实验室研究人员进行样本处理（资料图，非 Supernus 公司画面）。美国疾控中心 CDC 摄，公共领域，经 Wikimedia Commons。 / A laboratory researcher handling samples (file photo, not a Supernus facility). Photo by the U.S. Centers for Disease Control and Prevention, public domain, via Wikimedia Commons.
